Dynavax Technologies Corporation (DVAX) Position Raised by Renaissance Technologies LLC

Renaissance Technologies LLC increased its position in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 23.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 574,051 shares of the biopharmaceutical company’s stock after buying an additional 110,100 shares during the period. Renaissance Technologies LLC owned 1.29% of Dynavax Technologies Corporation worth $3,416,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of DVAX. DekaBank Deutsche Girozentrale bought a new position in shares of Dynavax Technologies Corporation during the first quarter worth $121,000. American International Group Inc. increased its position in shares of Dynavax Technologies Corporation by 7.1% in the first quarter. American International Group Inc. now owns 23,934 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 1,584 shares during the last quarter. Parametric Portfolio Associates LLC increased its position in shares of Dynavax Technologies Corporation by 3.6% in the first quarter. Parametric Portfolio Associates LLC now owns 27,151 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 939 shares during the last quarter. Nationwide Fund Advisors increased its position in shares of Dynavax Technologies Corporation by 11.2% in the first quarter. Nationwide Fund Advisors now owns 27,667 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 2,786 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in shares of Dynavax Technologies Corporation by 30.0% in the first quarter. Wells Fargo & Company MN now owns 41,743 shares of the biopharmaceutical company’s stock worth $248,000 after buying an additional 9,634 shares during the last quarter. 56.05% of the stock is currently owned by institutional investors and hedge funds.

Shares of Dynavax Technologies Corporation (NASDAQ DVAX) traded up 3.47% on Friday, reaching $16.40. The company’s stock had a trading volume of 727,881 shares. The company’s 50 day moving average is $11.52 and its 200-day moving average is $7.04. Dynavax Technologies Corporation has a 1-year low of $3.20 and a 1-year high of $19.60. The firm’s market cap is $897.85 million.

Dynavax Technologies Corporation (NASDAQ:DVAX) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. The firm had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.15 million. During the same period in the prior year, the firm posted ($0.75) earnings per share. Equities research analysts expect that Dynavax Technologies Corporation will post ($1.58) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/08/11/dynavax-technologies-corporation-dvax-position-raised-by-renaissance-technologies-llc.html.

A number of brokerages recently weighed in on DVAX. Royal Bank Of Canada set a $7.00 price objective on Dynavax Technologies Corporation and gave the company a “hold” rating in a research note on Wednesday, July 26th. Zacks Investment Research downgraded Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. ValuEngine downgraded Dynavax Technologies Corporation from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies Corporation in a research report on Thursday, July 27th. Finally, Cowen and Company reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Dynavax Technologies Corporation in a research report on Thursday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $23.34.

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Corporation (NASDAQ:DVAX).

Institutional Ownership by Quarter for Dynavax Technologies Corporation (NASDAQ:DVAX)

What are top analysts saying about Dynavax Technologies Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Dynavax Technologies Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit